By Jeremy Golden, BenzingaCardio Diagnostics, a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the.
Cardio Diagnostics (NASDAQ: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association (JAHA).
Shares of Cardio Diagnostics Holdings, Inc. (CDIO) are up 65% on Monday following the announcement of a groundbreaking study on the development and validation of PrecisionCHD, an innovative AI-guided integrated genetic-epigenetic test that can accurately detect coronary heart disease (CHD) through a simple blood draw.
Cardio Diagnostics (CDIO) Announces Publication of Breakthrough in Coronary Heart Disease Detection with PrecisionCHD Test streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cardio Diagnostics Holdings, Inc. announced the publication of its groundbreaking study in the Journal of the American Heart Association , an official journal of the American Heart Association. This.